| Journal of Clinical Medicine Research, ISSN 1918-3003 print, 1918-3011 online, Open Access |
| Article copyright, the authors; Journal compilation copyright, J Clin Med Res and Elmer Press Inc |
| Journal website https://www.jocmr.org |
Original Article
Volume 13, Number 6, June 2021, pages 355-362
Effect of Add-On Therapy of Sodium-Glucose Cotransporter 2 Inhibitors and Dipeptidyl Peptidase 4 Inhibitors on Adipokines in Type 2 Diabetes Mellitus
Tables
| Total | Group 1 | Group 2 | |
|---|---|---|---|
| Data are expressed as means ± SD, n (%). Group 1: metformin + DPP4 inhibitors. Group 2: metformin + SGLT2 inhibitors. DPP4: dipeptidyl peptidase 4; SGLT2: sodium-glucose cotransporter 2; BMI: body mass index; WC: waist circumference; BP: blood pressure. | |||
| Baseline characteristics | |||
| n | 90 | 30 | 60 |
| Men (n, %) | 67 (74.5%) | 20 (66.7%) | 47 (78.3%) |
| Women (n, %) | 23 (25.5%) | 10 (33.3%) | 13 (21.7%) |
| Smoking (n, %) | 13 (14.4%) | 5 (16.6%) | 8 (13.3%) |
| Hypertension (n, %) | 49 (54.4%) | 17 (56.6%) | 32 (53.3%) |
| Hypercholesterolemia (n, %) | 69 (76.6%) | 22 (73.3%) | 47 (78.3%) |
| Family history | |||
| Diabetes mellitus (n, %) | 69 (76.6%) | 23 (76.6%) | 46 (76.6%) |
| Hyper cholesterolemia (n, %) | 12 (13.3%) | 8 (26.6%) | 4 (6.6%) |
| Hypertension (n, %) | 36 (40%) | 11 (36.6%) | 25 (41.6%) |
| Clinical variables | |||
| Weight (kg) | 83.2 ± 10.2 | 80.4 ± 8.8 | 84.6 ± 10.7 |
| BMI (kg/m2) | 29.7 ± 2.7 | 29.2 ± 2.3 | 29.9 ± 2.8 |
| WC (cm) | 97.6 ± 4.7 | 96.0 ± 4.7 | 98.4 ± 4.5 |
| Systolic BP (mm Hg) | 120.5 ± 8.7 | 119.4 ± 9.7 | 121.1 ± 8.2 |
| Diastolic BP (mm Hg) | 76.7 ± 6.4 | 77.2 ± 7.7 | 76.5 ± 6.4 |
| Group | Number of subjects | Firstline therapy | Add-on therapy | Daily dosage |
|---|---|---|---|---|
| DPP4: dipeptidyl peptidase 4; SGLT2: sodium-glucose cotransporter 2 | ||||
| 1 (metformin + DPP4 inhibitors) | 30 | Metformin 1,000 mg (Glucophage®) | Sitagliptin/metformin 50 mg/1,000 mg (Janumet®) | One tablet two times per day |
| Vildagliptin/metformin 50 mg/1,000 mg (Galvusmet®) | One tablet two times per day | |||
| 2 (metformin + SGLT2 inhibitors) | 60 | Metformin 1,000 mg (Glucophage®) | Dapagliflozin/metformin 5 mg/1,000 mg (Xigduo®) | One tablet two times per day |
| Dapagliflozin/metformin 10 mg/1,000 mg (Xigduo®) | One tablet two times per day | |||
| Empagliflozin/metformin 5 mg/1,000 mg (Synjardy®) | One tablet two times per day | |||
| Empagliflozin/metformin 12.5 mg/1,000 mg (Synjardy®) | One tablet two times per day | |||